Tuesday, June 2, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Hodgkin and Non-Hodgkin Lymphomas


Kim Leake, MSN, FNP-C
UVA Health
Division of Hematology/Oncology
Emily Couric Clinical Cancer Center
Charlottesville, Virginia

Mollie Moran, APRN-CNP, AOCNP
The James Cancer Hospital at The Ohio State University
Columbus, Ohio

Craig Moskowitz, MD
Physician in Chief, Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor of Medicine, Miller School of Medicine
University of Miami Health System
Miami, Florida

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
Physician Lead, Cancer Service Line
University of Virginia School of Medicine
Charlottesville, Virginia


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Relative benefits and risks of various combination chemotherapy regimens for newly diagnosed advanced-stage Hodgkin lymphoma (HL)
  • Efficacy, safety and patient selection for brentuximab vedotin (BV) combined with AVD (doxorubicin/vinblastine/dacarbazine) as first-line therapy for advanced classical HL
  • Incidence and management of peripheral neuropathy and other toxicities associated with BV for HL
  • Role of BV in combination with chemo­therapy for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing PTCL
  • Clinical implications of available data with the R-squared regimen of lenalidomide/rituximab for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma
  • Treatment options for R/R follicular lymphoma; similarities and differences among PI3 kinase inhibitors (idelalisib, copanlisib and duvelisib) and appropriate integration into the management algorithm
  • Sequencing available treatment options for R/R mantle cell lymphoma (MCL)
  • Role of Bruton tyrosine kinase (BTK) inhibitors in the management of progressive MCL; differ­ences among ibrutinib, acalabrutinib and zanubrutinib
  • Optimal integration of lenalidomide into the treatment algorithm for R/R MCL; practical considerations, including prophylactic anticoagulation and antiplatelet therapy
  • Emerging efficacy and safety information with and potential role of venetoclax, alone or in combination with a BTK inhibitor, for patients with R/R MCL
  • Evidence-based treatment of newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL); importance of molecular subtype in prognosis and treatment course
  • Chimeric antigen receptor (CAR) T-cell therapy: Overview, biologic rationale and mechanism of action
  • Optimal timing for and considerations surrounding referral for CAR T-cell therapy
  • Available CAR T-cell platforms and effectiveness of CAR T-cell therapy for patients with R/R DLBCL; spectrum, frequency and management of toxicities, including cytokine release syndrome and neurotoxicity
  • FDA approval and practical implementation of polatuzumab vedotin in combination with bendamustine/rituximab for R/R DLBCL; dose, schedule and administration requirements and management of toxicities

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL), and use this information to enhance decision-making for patients.
  • Appraise the rationale for and available data documenting the utility of lenalidomide in combination with rituximab for newly diagnosed and R/R FL, and use this information to counsel patients regarding what role, if any, this regimen should play in their care.
  • Recognize the relevance of prior therapeutic exposure and patient and disease characteristics to the selection and sequencing of available systemic treatments for patients with R/R FL or MCL.
  • Appraise the similarities and differences among commercially available Bruton tyrosine kinase inhibitors, and counsel patients regarding the selection and sequencing of these agents in the management of  R/R MCL.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R DLBCL and other lymphomas for whom this approach may be appropriate.
  • Consider available clinical trial data and the scientific rationale for the evaluation of brentuximab vedotin in combination with AVD (doxorubicin/vinblastine/dacarbazine) to discern how this regimen can be optimally incorporated into front-line management of advanced classical HL.
  • Appreciate the recent FDA approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone for previously untreated CD30-positive PTCL, and counsel patients about the associated risks and benefits.
  • Educate patients about the side effects associated with approved therapies commonly used in the management of FL, MCL, DLBCL, HL and PTCL, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Describe available and emerging data with other investigational agents and strategies currently under evaluation for FL, MCL, DLBCL, HL and PTCL, and where applicable, refer eligible patients for trial participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with Hodgkin and non-Hodgkin lymphomas to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/Lymphomas/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Leake and Ms Moran have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr MoskowitzAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Seattle Genetics, Takeda Oncology; Contracted Research: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Merck, Seattle Genetics. Dr WilliamsAdvisory Committee: AbbVie Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Speakers Bureau: Xian Janssen Pharmaceutical Ltd.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.